A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

NCT ID: NCT05144854

Last Updated: 2024-09-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

626 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-11-05

Study Completion Date

2027-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is to compare and evaluate the efficacy and safety of ONO-4538 in combination with ipilimumab and chemotherapy versus chemotherapy in chemotherapy-naïve participants with HER2-negative unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastric Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ONO-4538 + ipilimumab + chemotherapy

Group Type EXPERIMENTAL

ONO-4538

Intervention Type DRUG

Specified dose on specified days

Ipilimumab

Intervention Type DRUG

Specified dose on specified days

Oxaliplatin

Intervention Type DRUG

Specified dose on specified days

Capecitabine

Intervention Type DRUG

Specified dose on specified days

S-1

Intervention Type DRUG

Specified dose on specified days

Chemotherapy

Group Type ACTIVE_COMPARATOR

Oxaliplatin

Intervention Type DRUG

Specified dose on specified days

Capecitabine

Intervention Type DRUG

Specified dose on specified days

S-1

Intervention Type DRUG

Specified dose on specified days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ONO-4538

Specified dose on specified days

Intervention Type DRUG

Ipilimumab

Specified dose on specified days

Intervention Type DRUG

Oxaliplatin

Specified dose on specified days

Intervention Type DRUG

Capecitabine

Specified dose on specified days

Intervention Type DRUG

S-1

Specified dose on specified days

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Nivolumab Opdivo BMS-734016 Yervoy Tegafur-gimeracil-oteracil potassium

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Participants with unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer) that has been histologically confirmed to be predominant adenocarcinoma
2. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score 0 or 1
3. Participants who have a life expectancy of at least 3 months

Exclusion Criteria

1. Participants with a history or complications of multiple cancers
2. Participants with a complication or history of severe hypersensitivity to any other antibody products
3. Participants with concurrent autoimmune disease or a history of chronic or recurrent autoimmune disease.
Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ono Pharmaceutical Co. Ltd

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Project Leader

Role: STUDY_DIRECTOR

Ono Pharmaceutical Co. Ltd

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Severance Hospital, Yonsei University Health System

Seoul, , South Korea

Site Status

The Catholic University of Korea, Seoul St. Mary's Hospital

Seoul, , South Korea

Site Status

Ulsan University Hospital

Ulsan, , South Korea

Site Status

Kaohsiung Chang Gung Memorial Hospital

Kaohsiung City, , Taiwan

Site Status

Kaohsiung Medical University Chung-Ho Memorial Hospital

Kaohsiung City, , Taiwan

Site Status

Chang Gung Memorial Hospital, Keelung

Keelung, , Taiwan

Site Status

Far Eastern Memorial Hospital

New Taipei City, , Taiwan

Site Status

Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare

New Taipei City, , Taiwan

Site Status

China Medical University Hospital

Taichung, , Taiwan

Site Status

Taichung Veterans General Hospital

Taichung, , Taiwan

Site Status

Chi Mei Hospital, Liouying

Tainan City, , Taiwan

Site Status

National Cheng Kung University Hospital

Tainan City, , Taiwan

Site Status

Koo Foundation Sun Yat-Sen Cancer Center

Taipei, , Taiwan

Site Status

National Taiwan University Hospital

Taipei, , Taiwan

Site Status

Taipei Medical University Hospital

Taipei, , Taiwan

Site Status

Taipei Municipal Wanfang Hospital Managed by Taipei Medical University

Taipei, , Taiwan

Site Status

Taipei Veterans General Hospital

Taipei, , Taiwan

Site Status

Tri-Service General Hospital

Taipei, , Taiwan

Site Status

Chang Gung Memorial Hospital,Linkou

Taoyuan, , Taiwan

Site Status

National Cancer Center Hospital East

Kashiwa-shi, Chiba, Japan

Site Status

Kanagawa Cancer Center

Yokohama, Kanagawa, Japan

Site Status

Osaki Citizen Hospital

Osaki-shi, Miyagi, Japan

Site Status

Osaka University Hospital

Suita-shi, Osaka, Japan

Site Status

Saitama Medical University International Medical Center

Hidaka-shi, Saitama, Japan

Site Status

Saitama Cancer Center

Ina-machi, Kitaadati-gun, Saitama, Japan

Site Status

Shizuoka Cancer Center

Nagaizumi-Cho, Sunto-Gun, Shizuoka, Japan

Site Status

University of Tokyo Hospital

Bunkyo-ku, Tokyo, Japan

Site Status

National Cancer Center Hospital

Chuo-ku, Tokyo, Japan

Site Status

Cancer Institute Hospital of JFCR

Koto-ku, Tokyo, Japan

Site Status

IMSUT Hospital, The Institute of Medical Science, The University of Tokyo

Minato-ku, Tokyo, Japan

Site Status

Keio University Hospital

Shinjyuku-ku, Tokyo, Japan

Site Status

Kosin University Gospel Hospital

Busan, Gangwon-do, South Korea

Site Status

Hallym University Sacred Heart Hospital

Anyang-si, Gyeonggi-do, South Korea

Site Status

National Cancer Center

Goyang-si, Gyeonggi-do, South Korea

Site Status

CHA Bundang Medical Center, CHA University

Seongnam-si, Gyeonggi-do, South Korea

Site Status

Seoul National University Bundang Hospital

Seongnam-si, Gyeonggi-do, South Korea

Site Status

Ajou University Hospital

Suwon, Gyeonggi-do, South Korea

Site Status

The Catholic University of Korea, St. Vincent's Hospital

Suwon, Gyeonggi-do, South Korea

Site Status

Kyungpook National University Chilgok Hospital

Daegu, Gyeongsangbuk-do, South Korea

Site Status

Pusan National University Yangsan Hospital

Yangsan, Gyeongsangnam-do, South Korea

Site Status

Jeonbuk national university hospital

Jeonju, Jeollabuk-do, South Korea

Site Status

Chonnam National University Hwasun Hospital

Hwasun-gun, Jeollanam-do, South Korea

Site Status

Chungbuk National University Hospital

Cheongju-si, North Chungcheong, South Korea

Site Status

Dong-A University Hospital

Busan, , South Korea

Site Status

Inje University Haeundae Paik Hospital

Busan, , South Korea

Site Status

Pusan National University Hospital

Busan, , South Korea

Site Status

Keimyung University Dongsan Hospital

Daegu, , South Korea

Site Status

Chungnam National University Hospital

Daejeon, , South Korea

Site Status

Konyang University Hospital

Daejeon, , South Korea

Site Status

Gachon University Gil Medical Center

Incheon, , South Korea

Site Status

Asan Medical Center

Seoul, , South Korea

Site Status

Chung-Ang University Hospital

Seoul, , South Korea

Site Status

Gangnam Severance Hospital, Yonsei University Health System

Seoul, , South Korea

Site Status

Kangbuk Samsung Hospital

Seoul, , South Korea

Site Status

Korea University Guro Hospital

Seoul, , South Korea

Site Status

Samsung Medical Center

Seoul, , South Korea

Site Status

Seoul National University Hospital

Seoul, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Japan South Korea Taiwan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ONO-4538-113

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.